United BioPharma (UBP) is a clinical stage
biopharmaceutical company, founded in 2013 as a spin-off from UBIAsia,
its parent company.
UBP is dedicated to research, development and manufacturing of novel
monoclonal antibodies (mAbs) for infectious diseases, cancer and immune disorders. With UBP’s Headquarters in Taiwan, subsidiary companies in Shanghai and Yangzhou China, and liaison offices in the US, we are a global team who are highly passionate about developing first-in-class, best-in-class therapeutic mAbs and delivering high-quality, affordable medicines to bring better life to the patients.
We are a private, closely held company and are proud to be one of the oldest biotech companies you may never have heard of. We enjoyed self-generated revenues and have funded our own R&D for many of these years. We do not have any own-branded novel products on the market, but have supported the sale of billions of units based on our technologies in human and animal health. We have a 30-year vision and are looking for partners with at least 15 to 30% of that patience.
We are passionate about delivering science -driven innovation with platform capabilities, and we want partners to help maximize our potential.
We are dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases through active (high precision designer vaccines) or passive (monoclonal antibodies) immunization.
In order to maximize our potential, we have formed various subsidiaries and affiliates to allow dedicated resources to support the development of products based on specific platform technologies, be that monoclonal antibodies, long acting protein drugs, or high precision designer vaccines. Through this type of corporate development strategy, we have built and developed strong internal expertise around each of the key platform technologies which empowers us to generate many innovative products derived thereof, followed by the enlistment of outside experts, leaders and collaborators to tackle a specific disease with its respective unmet need using our proprietary immuotherapeutic or vaccine.
We are an entrepreneurial biopharmaceutical company delivering life-changing solutions to improve global health.
We dedicate our scientific rigor to maintaining an innovation-driven, patient-oriented culture with outstanding execution and continuous improvement to fight diseases and improve medical interventions with unmet need.
Our foundation is our people. Every one shares in our vision and purpose. We transcend geographical boundaries to meet the ever-changing challenges of disease treatment. We believe that leadership is based on the courage to take risks, a sense of urgency, respect for people and the assurance that our integrity is never compromised.